Company News

IMS Health put itself up for sale, according to several reports citing people familiar with the matter. According to a Wall Street Journal report, the offers – from TPG, Silver Lake and BC Partners – are expected to give IMS stockholders a 30% premium on their shares, valuing the company at approximately $3.5 billion. Shares were up 21.6% - to $17.84 – following the WSJ report yesterday afternoon.

Bristol-Myers Squibb will cut roughly 25% of its Abilify sales force, according to a Bloomberg report. The cuts are a result of Otsuka Pharmaceuticals, a partner on the antipsychotic drug, taking over more of the marketing duties on Abilify, according to the report.  


You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.